Corporate Snapshot
Bioniche Life Sciences Inc. ("Bioniche" or "the Company") aims to improve the quality of life in both humans and animals through innovative research, technologies, and therapeutics. Bioniche is structured in three global business units: (1) Bioniche Therapeutics (Human Health); (2) Bioniche Animal Health; and (3) Bioniche Food Safety. The most advanced Human Health product candidate is Urocidin, a treatment for non-muscle-invasive bladder cancer that is in two Phase III clinical trials through a license agreement with Endo Pharmaceuticals (ENDP-NASDAQ). With a portfolio of over 60 products, Bioniche Animal Health develops products that enhance reproductive performance in animals and reduce the animal health industry's reliance on antibiotics. A lead Animal Health product is Folltropin-V, a reproductive hormone with an estimated 70% market share that induces superovulation in cattle and sheep. Bioniche Food Safety develops veterinary biopharmaceuticals to improve the safety of human food and water supplies. Its Econiche cattle vaccine reduces the level of E. coli O157:H7 shed by cattle, thus minimizing the risk of human illness from contaminated food or water. The vaccine has been fully licensed in Canada and was deemed eligible for a U.S. Department of Agriculture (USDA) conditional license in early 2008.
*The Corporate Snapshot was last updated on February 28, 2011.
Latest Research
Quarterly
Update
2011-02-28
Click to View
Quarterly
Update
2010-02-18
Click to View
Executive
Informational
Overview
2009-02-13
Click to View
* An earlier Executive Informational Overview was published on March 25, 2008. A copy of this report can be obtained by emailing eio@crystalra.com.
Stock Information (BNC-TSX; BNC-ASX)